Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss

Die redaktionellen Mitarbeiter sind am Ende des Beitrags gelistet

doi:10.1055/s-0029-1245534

Klinische Monatsblätter für Augenheilkunde, Inhaltsverzeichnis

Klin Monbl Augenheilkd 2010; 227(7): 542-556
DOI: 10.1055/s-0029-1245534

Statement

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss

Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on Therapy for Macular Oedema in Cases of Retinal Vein Occlusion Die redaktionellen Mitarbeiter sind am Ende des Beitrags gelistet¹

Abstract

Schlüsselwörter

Retinaler Venenverschluss - Zentralvenenverschluss - Venenastverschluss - intravitreale Injektion - Laserkoagulation

Key words

Retinal vein occlusion - Central retinal vein occlusion - branch retinal vein occlusion - intravitreal injection - laser photocoagulation

Volltext

Referenzen

Literatur

1 BVOS . Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol. 1986; 104 (1) 34-41
2 CVOS-Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. [comment]. Comment in: Ophthalmology. 1996;103 (3):352, discussion 353 – 354; PMID: 8 600 408, Comment in: Ophthalmology. 1996;103 (3):352, discussion 353 – 354; PMID: 8 600 407, Comment in: Ophthalmology. 1996;103 (3):352 – 354; PMID: 8 600 406. Ophthalmology. 1995; 102 (10) 1434-1444
3 Rogers S, McIntosh R L, Cheung N et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117 (2) 313-319 e1
4 David R, Zangwill L, Badarna M et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica. 1988; 197 (2) 69-74
5 Cugati S, Wang J J, Rochtchina E et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006; 124 (5) 726-732
6 Klein R, Klein B E, Moss S E et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000; 98 133-141 ; discussion 141 – 143
7 Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114 (10) 1243-1247
8 Cugati S, Cikamatana L, Wang J J et al. Five-year incidence and progression of vascular retinopathy in persons without diabetes: the Blue Mountains Eye Study. Eye. 2006; 20 (11) 1239-1245
9 Barnett E M, Fantin A, Wilson B S et al. The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study. Ophthalmology. 2010; 117 (3) 484-488
10 Hayreh S S. Retinal vein occlusion. [Review] [64 refs]. Indian Journal of Ophthalmology. 1994; 42 (3) 109-132
11 Dithmar S, Hansen L L, Holz F. Venöse retinale Verschlüsse. Ophthalmologe. 2003; 100 561-578
12 Klien B A, Olwin J H. A survey of the pathogenesis of retinal venous occlusion, emphasis upon choice of therapy and an analysis of the therapeutic results in fifty-three patients. AMA Arch Ophthalmol. 1956; 56 (2) 207-247
13 Hansen L L. [Treatment possibilities of central retinal vein occlusion] Behandlungsmöglichkeiten bei retinalen Zentralvenenverschlüssen. Ophthalmologe. 1994; 91 (1) 131-145
14 Green W R, Chan C C, Hutchins G M et al. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981; 1 (1) 27-55
15 Hayreh S S. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005; 24 (4) 493-519
16 Brown G. Central retinal vein obstruction: diagnosis and management. Reinecke RD, Editor Appleton&Lange Ophthalmol Annual; 1985: 65-97
17 Cugati S, Wang J J, Knudtson M D et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007; 114 (3) 520-524
18 Hayreh S S, Zimmerman M B, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994; 117 (4) 429-441
19 Fegan C D. Central retinal vein occlusion and thrombophilia. Eye. 2002; 16 (1) 98-106
20 Fong A C, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993; 37 (6) 393-417
21 Hayreh S S, Zimmerman M B, Beri M et al. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology. 2004; 111 (1) 133-141
22 Hansen L L. Central retinal vein occlusion. A Joussen, et al Retinal Vascular Disease Springer; 2007
23 Hayreh S S, Hayreh M S. Hemi-central retinal vein occlusion. Pathogenesis, clinical features, and natural history. Arch Ophthalmol. 1980; 98 (9) 1600-1609
24 CVOS-Group . Baseline and early natural history report. The Central Vein Occlusion Study. [comment]. Comment in: Arch Ophthalmol 1995;113 (5):555; PMID: 7 605 492. Archives of Ophthalmology. 1993; 111 (8) 1087-1095
25 BVOS . Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984; 98 (3) 271-282
26 CVOS . Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group. Online J Curr Clin Trials. 1993; Doc No 92
27 Quinlan P M, Elman M J, Bhatt A K et al. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990; 110 (2) 118-123
28 CVOS-Group . Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. [comment]. [erratum appears in Arch Ophthalmol 1997;115 (10):1275]. Comment in: Arch Ophthalmol 1998;116 (2):260 – 261; PMID: 9 488 292. Archives of Ophthalmology. 1997; 115 (4) 486-491
29 Wroblewski J J, Wells 3 rd J A, Adamis A P et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009; 127 (4) 374-380
30 Brown D M, Campochiaro P A, Singh R P et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. 2010; online
31 Campochiaro P A, Heier J S, Feiner L et al. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. 2010; ; online
32 Gutman F A, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974; 78 (2) OP178-OP192
33 Michels R G, Gass J D. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol. 1974; 78 (2) OP166-OP177
34 Joffe L, Goldberg R E, Magargal L E et al. Macular branch vein occlusion. Ophthalmology. 1980; 87 (2) 91-98
35 Notting J G, Werf P J. Macular changes caused by occlusion of a minute venous branch. Ophthalmologica. 1976; 173 (3 – 4) 200-206
36 Parodi M B, Visintin F, Della Rupe P et al. Foveal avascular zone in macular branch retinal vein occlusion. Int Ophthalmol. 1995; 19 (1) 25-28
37 Duff I F, Falls H F, Linman J W. Anticoagulant therapy in occlusive vascular disease of the retina. AMA Arch Ophthalmol. 1951; 46 (6) 601-617
38 Holmin N, Ploman K. Thrombosis of the central retinal vein of the retina treated with heparin. Lancet. 1938; 1 664-671
39 Vannas S, Raitta C. Anticoagulant treatment of retinal venous occlusion. Am J Ophthalmol. 1966; 62 (5) 874-884
40 Ageno W, Cattaneo R, Manfredi E et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res. 2010; 125 (2) 137-141
41 Farahvash M S, Moghaddam M M, Moghimi S et al. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol. 2008; 43 (1) 79-83
42 Farahvash M S, Moradimogadam M, Farahvash M M et al. Dalteparin versus Aspirin in Recent-Onset Branch Retinal Vein Occlusion: A Randomized Clinical Trial. Arch Iran Med. 2008; 11 (4) 418-422
43 Steigerwalt R D, Cesarone M R, Belcaro Jr G et al. Retinal and orbital venous occlusions treated with enoxaparin. J Ocul Pharmacol Ther. 2008; 24 (4) 421-426
44 Browning D J, Fraser C M. Retinal vein occlusions in patients taking warfarin. Ophthalmology. 2004; 111 (6) 1196-1200
45 Rosengreen B. The value of anti-coagulators in the treatment of retinal thrombosis. Acta Ophthalmol. 1948; 26 275-280
46 Schlosshardt H. [Observations and results of photodocumentation of retinal thromboses treated with Colfarit (author’s transl)] Beobachtungen und Erkenntnisse bei der Fotodokumentation mit Colfarit behandelter Netzhautthrombosen. Klin Monatsbl Augenheilkd. 1978; 172 (6) 895-907
47 Squizzato A, Manfredi E, Bozzato S et al. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: A systematic review and a call for action. Thromb Haemost. 2010; 103 (2) 271-276
48 Ingerslev J. Thrombophilia: a feature of importance in retinal vein thrombosis?. Acta Ophthalmol Scand. 1999; 77 (6) 619-621
49 Antonetti D A, Barber A J, Hollinger L A et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999; 274 (33) 23 463-23 467
50 Fonollosa A, Garcia-Arumi J, Santos E et al. Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion. Eye. 2010; im Druck
51 Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005; 140 (2) 256-261
52 Noma H, Minamoto A, Funatsu H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006; 244 (3) 309-315
53 Romero I A, Radewicz K, Jubin E et al. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett. 2003; 344 (2) 112-116
54 Park D H, Kim I T. Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion. Retina. 2010; 30 (1) 117-124
55 Naumann G. Pathologie des Auges. Embryologie, Anatomie und Untersuchungstechnik. 2 ed. Berlin: Springer; 1997. 2 ed.: 1008-1012
56 Seitz R. Die Netzhautgefäße. Thiel R Bücherei des Augenarztes,. Vol. 40 1 ed. Stuttgart: Ferdinand Enke Verlag; 1962: 175
57 Maruo N, Morita I, Shirao M et al. IL-6 increases endothelial permeability in vitro. Endocrinology. 1992; 131 (2) 710-714
58 Kaiser P K. Steroids for branch retinal vein occlusion. Am J Ophthalmol. 2005; 139 (6) 1095-1096
59 Folkman J, Ingber D E. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg. 1987; 206 (3) 374-383
60 Brückner R. Central retinal vein occlusion and its therapy. Ophthalmologica. 1955; 129 325-326
61 Hayreh S S. Classification of central retinal vein occlusion. Ophthalmology. 1983; 90 (5) 458-474
62 Shaikh S, Blumenkranz M S. Transient improvement in visual acuity and macular edema in central retinal vein occlusion accompanied by inflammatory features after pulse steroid and anti-inflammatory therapy. Retina. 2001; 21 (2) 176-178
63 Glacet-Bernard A, Zourdani A, Milhoub M et al. Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Archive for Clinical & Experimental Ophthalmology. 2001; 239 (12) 909-914
64 Neely K A, Ernest J T, Goldstick T K et al. Isovolemic hemodilution increases retinal tissue oxygen tension. Graefes Arch Clin Exp Ophthalmol. 1996; 234 (11) 688-694
65 Wiek J, Schade M, Wiederholt M et al. Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution. Br J Ophthalmol. 1990; 74 (11) 665-669
66 Long D S, Smith M L, Pries A R et al. Microviscometry reveals reduced blood viscosity and altered shear rate and shear stress profiles in microvessels after hemodilution. Proc Natl Acad Sci U S A. 2004; 101 (27) 10 060-10 065
67 Nagaoka T, Yoshida A. Noninvasive evaluation of wall shear stress on retinal microcirculation in humans. Invest Ophthalmol Vis Sci. 2006; 47 (3) 1113-1119
68 Peduzzi M, Codeluppi L, Poggi M et al. Abnormal blood viscosity and erythrocyte deformability in retinal vein occlusion. Am J Ophthalmol. 1983; 96 (3) 399-400
69 McGrath M A, Wechsler F, Hunyor A B et al. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978; 138 (2) 216-220
70 Ring C P, Pearson T C, Sanders M D et al. Viscosity and retinal vein thrombosis. Br J Ophthalmol. 1976; 60 (6) 397-410
71 Trope G E, Lowe G D, McArdle B M et al. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol. 1983; 67 (3) 137-142
72 Genevois O, Paques M, Simonutti M et al. Microvascular remodeling after occlusion-recanalization of a branch retinal vein in rats. Invest Ophthalmol Vis Sci. 2004; 45 (2) 594-600
73 Danis R P, Wallow I CH. Microvascular changes in experimental branch retinal vein occlusion. Ophthalmology. 1987; 94 (10) 1213-1221
74 Heinen A, Brunner R, Hossmann V et al. [Changes in hemorheologic and physiologic coagulation parameters in different methods of therapy of retinal vascular disorders – a randomized double-blind study] Veränderungen hamorheologischer und gerinnungsphysiologischer Parameter bei unterschiedlicher Therapie von retinalen Durchblutungsstörungen – eine randomisierte Doppelblindstudie. Fortschr Ophthalmol. 1984; 81 (5) 444-448
75 Jung F, Koscielny J, Mrowietz C et al. [Effect of hemodilution on systemic and capillary hematocrit] Einfluss der Hamodilution auf den systemischen und den Kapillarhämatokrit. Infusionstherapie. 1990; 17 (5) 268-275
76 Hansen L L, Danisevskis P, Arntz H R et al. A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol. 1985; 69 (2) 108-116
77 Hansen L L, Hovener G, Mercks C et al. [Isovolemic hemodilution in patients with retinal branch vein occlusion] Isovolämische Hämodilution bei Patienten mit retinalen Venenastverschlüssen. Fortschr Ophthalmol. 1985; 82 (3) 290-292
78 Hansen L L, Wiek J, Schade M et al. Effect and compatibility of isovolaemic haemodilution in the treatment of ischaemic and non-ischaemic central retinal vein occlusion. Ophthalmologica. 1989; 199 (2 – 3) 90-99
79 Hansen L L, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol. 1989; 73 (11) 895-899
80 Luckie A P, Wroblewski J J, Hamilton P et al. A randomised prospective study of outpatient haemodilution for central retinal vein obstruction. Aust N Z J Ophthalmol. 1996; 24 (3) 223-232
81 Wolf S, Arend O, Bertram B et al. Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol. 1994; 232 (1) 33-39
82 Wolf S, Arendt O, Bertram B et al. Hemodilution therapy in central retinal vein occlusion. A randomized placebo-controlled study. Fortschr Ophthalmol. 1991; 88 35-43
83 Donati G, Mavrakanas N, Pournaras C J. [Isovolumic hemodilution in the management of the acute phase of central retinal vein occlusion: A pilot study]. J Fr Ophtalmol. 2009; 32 (10) 750-756
84 Hansen L L, Wiek J, Arntz R. [Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion] Randomisierte Studie zur Wirkung der isovolämischen Hämodilution bei retinalen Venenastverschlüssen. Fortschr Ophthalmol. 1988; 85 (5) 514-516
85 McIntosh R L, Mohamed Q, Saw S M et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007; 114 (5) 835-854
86 Mohamed Q, McIntosh R L, Saw S M et al. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007; 114 (3) 507-519
87 Chen H C, Wiek J, Gupta A et al. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. British Journal of Ophthalmology. 1998; 82 (2) 162-167
88 CVOS-Group . Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. [comment]. Comment in: Ophthalmology. 1996 Mar;103 (3):352, discussion 353 – 4; PMID: 8 600 408, Comment in: Ophthalmology 1996;103 (3):352, discussion 353 – 354; PMID: 8 600 407, Comment in: Ophthalmology 1996;103 (3):352 – 354; PMID: 8 600 406. Ophthalmology. 1995; 102 (10) 1425-1433
89 Gutman F A, Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol. 1984; 28 Suppl 462-470
90 Klein M L, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol. 1989; 107 (9) 1297-1302
91 Finkelstein D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol. 1992; 110 (10) 1427-1434
92 Kiryu J, Ogura Y. Hyperbaric oxygen treatment for macular edema in retinal vein occlusion: relation to severity of retinal leakage. Ophthalmologica. 1996; 210 (3) 168-170
93 Battaglia Parodi M, Saviano S, Bergamini L et al. Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc Ophthalmol. 1999; 97 (3 – 4) 427-431
94 Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1999; 237 (12) 1024-1027
95 McAllister I L, Yu D Y, Vijayasekaran S et al. Induced chorioretinal venous anastomosis in experimental retinal branch vein occlusion. Br J Ophthalmol. 1992; 76 (10) 615-20
96 Bill A. The uveal venous pressure. Arch Ophthalmol. 1963; 69 780-782
97 Fekrat S, Goldberg M F, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol. 1998; 116 (1) 43-52
98 Eckstein M, McAllister I. Laser-induced chorioretinal venous anastomosis for non-ischaemic hemi-central vein occlusion. Clin Experiment Ophthalmol. 2000; 28 (1) 18-21
99 McAllister I L, Barry C J. Collateral formation in hemicentral retinal vein occlusion. Aust N Z J Ophthalmol. 1991; 19 (3) 239-241
100 McAllister I L, Constable I J. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995; 113 (4) 456-462
101 McAllister I L, Douglas J P, Constable I J et al. Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol. 1998; 126 (2) 219-229
102 McAllister I L, Vijayasekaran S, Yu D Y et al. Chorioretinal venous anastomoses: effect of different laser methods and energy in human eyes without vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1998; 236 (3) 174-181
103 McAllister I L, Gillies M E, Smithies L A et al. The Central Retinal Vein Bypass Study: A Trial of Laser-induced Chorioretinal Venous Anastomosis for Central Retinal Vein Occlusion. Ophthalmology. 2010; 117 (5) 954-965
104 Browning D J, Antoszyk A N. Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion. Ophthalmology. 1998; 105 (4) 670-677 ; discussion 677 – 679
105 Browning D J, Rotberg M H. Vitreous Hemorrhage complicating laser-induced chorioretinal anastomosis for central retinal vein occlusion. Am J Ophthalmol. 1996; 122 (4) 588-589
106 Bavbek T, Yenice O, Toygar O. Problems with attempted chorioretinal venous anastomosis by laser for nonischemic CRVO and BRVO. Ophthalmologica. 2005; 219 (5) 267-271
107 Sedney S. Photocoagulation and retinal vein occlusion. Documenta Ophthalmologica. 1976; 40 1-241
108 Oncel M, Peyman G A, Khoobehi B. Tissue plasminogen activator in the treatment of experimental retinal vein occlusion. Retina. 1989; 9 (1) 1-7
109 Elman M J. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc. 1996; 94 471-504
110 Kohner E M, Hamilton A M, Bulpitt C J et al. Streptokinase in the treatment of central retinal vein occlusion. A controlled trial. Trans Ophthalmol Soc U K. 1974; 94 (2) 599-603
111 Kohner E M, Pettit J E, Hamilton A M et al. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J. 1976; 1 (6009) 550-553
112 Hattenbach L O, Friedrich Arndt C, Lerche R et al. Retinal vein occlusion and low-dose fibrinolytic therapy (ROLF): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina. 2009; 29 (7) 932-940
113 Elman M J, Raden R Z, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc. 2001; 99 219-221 ; discussion 222 – 223
114 Glacet-Bernard A, Kuhn D, Vine A K et al. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000; 84 (6) 609-613
115 Paques M, Vallee J N, Herbreteau D et al. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Br J Ophthalmol. 2000; 84 (12) 1387-1391
116 Noma H, Funatsu H, Sakata K et al. Macular microcirculation and macular oedema in branch retinal vein occlusion. Br J Ophthalmol. 2009; 93 (5) 630-633
117 Raszewska-Steglinska M, Gozdek P, Cisiecki S et al. Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol. 2009; 19 (6) 1055-1062
118 Gupta B, Grewal J, Adewoyin T et al. Diurnal variation of macular oedema in CRVO: prospective study. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (5) 593-596
119 DeCroos F C, Shuler R RK, Stinnett Jr S et al. Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion. Am J Ophthalmol. 2009; 147 (4) 627-633 e1
120 Sekiryu T, Yamauchi T, Enaida H et al. Retina tomography after vitrectomy for macular edema of central retinal vein occlusion. Ophthalmic Surg Lasers. 2000; 31 (3) 198-202
121 Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol. 1999; 97 (3 – 4) 465-469
122 Hikichi T, Konno S, Trempe C L. Role of the vitreous in central retinal vein occlusion. Retina. 1995; 15 (1) 29-33
123 Stefansson E, Novack R L, Hatchell D L. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 1990; 31 (2) 284-289
124 Kumagai K, Furukawa M, Ogino N et al. Long-Term Visual Outcomes after Vitrectomy for Macular Edema with Foveal Hemorrhage in Branch Retinal Vein Occlusion. Retina. 2007; 27 (5) 584-588
125 Noma H, Funatsu H, Sakata K et al. Macular microcirculation before and after vitrectomy for macular edema with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010; 248 (3) 443-445
126 Williamson T H, Grewal J, Gupta B et al. Measurement of PO 2 during vitrectomy for central retinal vein occlusion, a pilot study. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (8) 1019-1023
127 Osterloh M. Surgical decompression of branch retinal vein occlusions. Archives of Ophthalmology. 1988; 106 (10) 1469-1471
128 Kumagai K, Furukawa M, Ogino N et al. Long-Term Outcomes of Vitrectomy with or without Arteriovenous Sheathotomy in Branch Retinal Vein Occlusion. Retina. 2007; 27 (1) 49-54
129 Yamamoto S, Saito W, Yagi F et al. Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2004; 138 (6) 907-914
130 Vasco-Posada J. Modification of the circulation in the posterior pole of the eye. Ann Ophthalmol. 1972; 4 (1) 48-59
131 Opremcak E M, Bruce R A, Lomeo M D et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001; 21 (5) 408-415
132 Arevalo J F, Garcia R A, Wu L et al. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina. 2008; 28 (8) 1044-1052
133 Feltgen N, Herrmann J, Hansen L. [Visual field defect after radial optic neurotomy] Gesichtsfelddefekt nach radiärer Optikoneurotomie. Ophthalmologe. 2005; 102 (8) 802-804
134 Hasselbach H, Thale A, Bunse A et al. Ultrastructural analysis of the lamina cribrosa after radial optic neurotomy. Ann Anat. 2009; 191 (3) 267-272
135 Hayreh S S. Radial optic neurotomy for central retinal vein occlusion. Retina. 2002; 22 (6) 827 ; author reply 827
136 Lit E S, Tsilimbaris M, Gotzaridis E et al. Lamina puncture: pars plana optic disc surgery for central retinal vein occlusion. Archives of Ophthalmology. 2002; 120 (4) 495-499
137 Yamamoto S, Takatsuna Y, Sato E et al. Central retinal artery occlusion after radial optic neurotomy in a patient with central retinal vein occlusion. Am J Ophthalmol. 2005; 139 (1) 206-207
138 Yamamoto T, Kamei M, Sakaguchi H et al. Comparison of surgical treatments for central retinal vein occlusion, RON vs. cannulation of tissue plasminogen activator into the retinal vein. Retina. 2009; 29 (8) 1167-1174
139 Hasselbach H C, Ruefer F, Feltgen N et al. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefes Arch Clin Exp Ophthalmol. 2007; 245 (8) 1145-1156
140 Vogel A, Holz F G, Loeffler K U. Histopathologic findings after radial optic neurotomy in central retinal vein occlusion. Am J Ophthalmol. 2006; 141 (1) 203-205
141 Czajka M, Pecold K. [Radial optic neurotomy (RON) in central retinal vein occlusion (CRVO) – preliminary report]. Klin Oczna. 2004; 106 (6) 774-777
142 Jumper J M, Scribbick F W, Ho J et al. Pathologic evaluation of radial optic neurotomy in an animal model. Retina. 2006; 26 (3) 362-364
143 Tao Y, Jiang Y R, Li X X et al. Fundus and histopathological study of radial optic neurotomy in the normal miniature pig eye. Arch Ophthalmol. 2005; 123 (8) 1097-1101
144 Bynoe L A, Opremcak E M, Bruce R A et al. Radial optic neurotomy for central retinal vein obstruction. Retina. 2002; 22 (3) 379-380 ; author reply 380 – 381
145 Wrede J, Varadi G, Volcker H E et al. [Radial optic neurotomy for central retinal vein occlusion – how deep should it be? ] Wie tief muss die radiäre Optikusneurotomie zur Therapie des retinalen Zentralvenenverschlusses sein?. Ophthalmologe. 2006; 103 (4) 321-324
146 Friberg T R, Smolinski P, Hill S et al. Biomechanical assessment of radial optic neurotomy. Ophthalmology. 2008; 115 (1) 174-180
147 Weiss J N. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol. 1998; 126 (1) 142-144
148 Bynoe L A, Hutchins R K, Lazarus H S et al. Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons. Retina. 2005; 25 (5) 625-632
149 Bynoe L A, Weiss J N. Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. American Journal of Ophthalmology. 2003; 135 (3) 382-384
150 Weiss J N, Bynoe L A. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology. 2001; 108 (12) 2249-2257
151 Feltgen N, Agostini H, Auw-Haedrich C et al. Histopathological findings after retinal endovascular lysis in central retinal vein occlusion. Br J Ophthalmol. 2007; 91 (4) 558-559
152 Feltgen N, Junker B, Agostini H et al. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology. 2007; 114 (4) 716-723
153 Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2005; 139 (6) 972-982
154 Hayreh S S. Management of central retinal vein occlusion. Ophthalmologica. 2003; 217 (3) 167-188
155 Wilson C A, Berkowitz B A, Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110 (8) 1155-1159
156 Kube T, Sutter M, Trittler R et al. Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol. 2006; 244 (11) 1385-1390
157 Ip M S, Scott I U, VanVeldhuisen P C et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care v. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009; 127 (9) 1101-1114
158 Scott I U, Ip M S, VanVeldhuisen P C et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009; 127 (9) 1115-1128
159 Chu Y K, Chung E J, Kwon O W et al. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye (Lond). 2008; 22 (7) 895-899
160 Bashshur Z F, Ma’luf R N, Allam S et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004; 122 (8) 1137-1140
161 Jaissle G B, Szurman P, Volker M et al. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging. 2007; 38 (3) 238-241
162 Luke M, Januschowski K, Beutel J et al. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res. 2008; 87 (1) 22-29
163 Haller J A, Bandello F, Belfort Jr R et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010; ; online
164 Hardman J, Limbird L. Goodman and Gilman’s: the pharmacological basis of therapeutics. in Hardman J, Editors Goodman and Gilman’s: the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996
165 Nehme A, Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci. 2008; 49 (5) 2030-2038
166 Gan I M, Ugahary L C, Dissel J T et al. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005; 243 (11) 1186-1189
167 Kuppermann B D, Blumenkranz M S, Haller J A et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007; 125 (3) 309-317
168 Haller J A, Dugel van P, Weinberg D V et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009; 29 (1) 46-51
169 [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration] Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd. 2007; 224 (7) 559-566
170 Rosenfeld P J, Fung A E, Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005; 36 (4) 336-339
171 Wroblewski J J, Wells 3 rd J A, Gonzales C R. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010; 149 (1) 147-154
172 Wu L, Arevalo J F, Berrocal M H et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina. 2009; 29 (10) 1396-1403
173 Wu L, Arevalo J F, Roca J A et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008; 28 (2) 212-219
174 Jaissle G B, Ziemssen F, Petermeier K et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion] Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefässverschlüssen. Ophthalmologe. 2006; 103 (6) 471-475
175 Iturralde D, Spaide R F, Meyerle C B et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006; 26 (3) 279-284
176 Stahl A, Agostini H, Hansen L L et al. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol. 2007; 245 (10) 1429-1436
177 Stahl A, Feltgen N, Fuchs A et al. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol. 2009; 118 (2) 81-88
178 Tao Y, Hou J, Jiang Y R et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye. 2010; 24 (5) 810-815
179 Schaal K B, Hoh A E, Scheuerle A et al. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion] Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefässverschlüsse. Ophthalmologe. 2007; 104 (4) 285-289
180 Jaissle G B, Leitritz M, Gelisken F et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (1) 27-33
181 Priglinger S G, Wolf A H, Kreutzer T C et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007; 27 (8) 1004-1012
182 Rabena M D, Pieramici D J, Castellarin A A et al. Intravitreal Bevacizumab (Avastin) in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. Retina. 2007; 27 (4) 419-425
183 Gutierrez J C, Barquet L A, Caminal J M et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Clin Ophthalmol. 2008; 2 (4) 787-791
184 Gregori N Z, Gaitan J, Rosenfeld P J et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina. 2008; 28 (9) 1325-1337
185 Gregori N Z, Rattan G H, Rosenfeld P J et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009; 29 (7) 913-925
186 Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008; 92 (4) 518-522
187 Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008; 19 (3) 234-238
188 Stahl A, Struebin I, Hansen L L et al. Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol. 2010; 20 (1) 180-185
189 Wu W C, Cheng K C, Wu H J. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye. 2009; 23 (12) 2215-2222
190 Hoeh A E, Ach T, Schaal K B et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (12) 1635-1641
191 Gregori N Z, Rosenfeld P J, Puliafito C A et al. One-Year Safety and Efficacy of Intravitreal Triamcinolone Acetonide for the Management of Macular Edema Secondary to Central Retinal Vein Occlusion. Retina. 2006; 26 (8) 889-895
192 Kreutzer T C, Alge C S, Wolf A H et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008; 92 (3) 351-355
193 Kondo M, Kondo N, Ito Y et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis. Retina. 2009; 29 (9) 1242-1248
194 Pai S A, Shetty R, Vijayan P B et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol. 2007; 143 (4) 601-606
195 Matsumoto Y, Freund K B, Peiretti E et al. Rebound macular edema following bevacizumab (avastin) therapy for retinal venous occlusive disease. Retina. 2007; 27 (4) 426-431
196 Alasil T, Rauser M E. Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report. Cases J. 2009; 2 176
197 Ciftci S, Sakalar Y B, Unlu K et al. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthalmol. 2009; 19 (6) 1028-1033
198 Hasanreisoglu M, Weinberger D, Mimouni K et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. 2009; 19 (4) 607-612
199 Yuzbasioglu E, Artunay O, Rasier R et al. Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma. J Ocul Pharmacol Ther. 2009; 25 (3) 259-264
200 Costagliola C, Cipollone U, Rinaldi M et al. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol. 2008; 66 (5) 667-673
201 Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007; 16 (5) 437-439
202 Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008; 28 (1) 59-61
203 Lynch S S, Cheng C M. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007; 41 (4) 614-625
204 Iliev M E, Domig D, Wolf-Schnurrbursch U et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006; 142 (6) 1054-1056
205 Grisanti S, Biester S, Peters S et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006; 142 (1) 158-160
206 Kahook M Y, Schuman J S, Noecker R J. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006; 37 (2) 144-146
207 Campochiaro P A, Hafiz G, Shah S M et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008; 16 (4) 791-799
208 Pieramici D J, Rabena M, Castellarin A A et al. Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions. Ophthalmology. 2008; 115 (10) e47-e54
209 Rouvas A, Petrou P, Vergados I et al. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (12) 1609-1616
210 Spaide R F, Chang L K, Klancnik J M et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009; 147 (2) 298-306
211 Christoffersen N, Gade E, Knudsen L et al. Mortality in patients with branch retinal vein occlusion. Ophthalmology. 2007; 114 (6) 1186-1189
212 O’Mahoney P R, Wong D T, Ray J G. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008; 126 (5) 692-699
213 Ho J D, Liou S W, Lin H C. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol. 2009; 147 (2) 283-290 e2
214 Dodson P M, Kubicki A J, Taylor K G et al. Medical conditions underlying recurrence of retinal vein occlusion. Br J Ophthalmol. 1985; 69 (7) 493-496
215 Kuhli C, Hattenbach L O, Scharrer I et al. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (3) 163-168
216 Kuhli C, Scharrer I, Koch F et al. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol. 2004; 137 (3) 459-464
217 Kuhli-Hattenbach C, Scharrer I, Luchtenberg M et al. Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost. 2010; 103 (2) 299-305
218 Kuhli-Hattenbach C, Scharrer I, Luchtenberg M et al. [Selective thrombophilia screening of young patients with retinal vein occlusion] Selektives Thrombophiliescreening junger Patienten mit venösen retinalen Gefässverschlüssen. Klin Monatsbl Augenheilkd. 2009; 226 (9) 768-773
219 Hayreh S S, Rojas P, Podhajsky P et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983; 90 (5) 488-506
220 Hoerauf H. Branch retinal vein occlusion. in Joussen A, Editors Retinal vascular diseases. Heidelberg: Springer; 2007: 467-506
221 Russo V, Barone A, Conte E et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009; 29 (4) 511-515
222 Byun Y J, Roh M I, Lee S C et al. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010; 248 (7) 963-971
223 Guthoff R, Meigen T, Hennemann K et al. Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion – A Matched-Pairs Analysis. Ophthalmologica. 2009; 224 (2) 126-132
224 Hou J, Tao Y, Jiang Y R et al. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J. 2009; 122 (22) 2695-2699
225 Kim J Y, Park S P. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2009; 23 (4) 259-265